Prediction of Clinical Response to 5-Fluorouracil-Containing Chemotherapy: Preliminary Results of in Vitro Assay in Human Breast Cancer

  • B. Ardalan
  • J. Macdonald
  • D. Cooney
  • M. Lippman
  • P. Schein
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 74)


An in vitro assay system measuring the production of phosphorylated nucleotide products of 5-FU by human tumor cytosols is described. Samples from 11 patients with breast cancer treated with 5-FU-containing chemotherapy regimens were assayed. Significant differences were seen in quantitative and qualitative patterns of phosphorylation between samples from chemotherapy responding and nonresponding patients. The rate of 5-fluorodeoxyuridylate production and the amount of nucleotide triphosphate produced were significantly P < 0.05 increased in chemotherapy-re- sponding patients. This in vitro assay system is a simple, reproducible procedure that requires further evaluation as a potential system for prospectively predicting clinical response to fluorinated pyrimidines.


Human Breast Cancer Cytosol Fraction Tritiated Water Pyrimidine Nucleoside Combination Chemotherapy Regimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ardalan B, Macdonald JS, Cooney D, Schein PS (1979) Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors. Bull Cancer 66:55–59PubMedGoogle Scholar
  2. 2.
    Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC (1976) Combination chemotherapy for advanced breast cancer: Response and effect on survival. Ann Intern Med 84:389–392PubMedGoogle Scholar
  3. 3.
    Duschnisky R, Pleven E (1957) The synthesis of 5-fluoro-pyrimidines. J Am Chem Soc 79:4559–4560CrossRefGoogle Scholar
  4. 4.
    Friedman MA, Sadee W (1978) The fluoropyrimidines: Biochemical mechanisms and design of clinical trials. Cancer Chemother Pharmacol 1:77–82PubMedCrossRefGoogle Scholar
  5. 5.
    Heidelberger C (1965) Fluorinated pyrimidines. Prog Nucleic Acid Res Mol Biol 4:1–50PubMedCrossRefGoogle Scholar
  6. 6.
    Heidelberger C, Chaudhuri NK, Pleven E, Scheiner J (1957) Fluorinated pyrimidines, a new class of tumor-inhibiting compounds. Nature 179:663–666PubMedCrossRefGoogle Scholar
  7. 7.
    Heidelberger C, Greisbach L, Montag BJ, Mooren D, Cruz O, Schneizer RJ, Grunberg E (1958) Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Res 18:305–317PubMedGoogle Scholar
  8. 8.
    Livingston RB, Carter SK (1970) Single agents in cancer chemotherapy. Plenum, New YorkGoogle Scholar
  9. 9.
    Roberts D (1966) An isotopic assay for thymidylate synthetase. Biochemistry 5:3546–3548PubMedCrossRefGoogle Scholar
  10. 10.
    Sawyer R, Nayak R, Spiegelman S, Martin D (1979) Mechanism of action of 5-fluorouracil (FU) in the chemotherapy of the murine mammary tumor. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:263Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • B. Ardalan
  • J. Macdonald
  • D. Cooney
  • M. Lippman
  • P. Schein

There are no affiliations available

Personalised recommendations